

# **Antimicrobial Resistance Symposium**

Partnering to accelerate antibiotic development and access to tackle drugresistant bacterial infections

Berlin, 15 May 2024

Charité Cross Over (CCO)
Virchowweg 6, 10117 Berlin
Charité - Universitätsmedizin Berlin

# **Hybrid Event in English**

# Background

Nearly five million deaths are associated with antimicrobial resistance (AMR). Children and newborns are especially vulnerable to drug-resistant bacteria. 1 in 5 deaths caused by antibiotic resistance occur in children under the age of five, and up to 3 million newborns get serious infections that lead to life-threatening conditions every year.

Very few innovative new antibiotics have come to the market in the past years and resistance against these new agents develops faster than ever. There are many bottlenecks and challenges to the development, access and stewardship of new antibiotics to address the growing burden of drug-resistant infections, and especially those priority pathogens identified by the World Health Organization (WHO).

The symposium will serve to identify several of the bottlenecks to development, access, and stewardship and examine how partnerships that bring together the resources, expertise, and cooperation of the public, private, and not-for-profit sectors can best overcome these challenges and ensure the right antibiotic at the right time can reach patients in need.

Programme	
8:00- 8:30	Arrival of participants and registration
8:30 - 8:50	<ul> <li>Welcome</li> <li>Beate Kampmann, Director, Charité Centre for Global Health, Charité - Universitätsmedizin Berlin</li> <li>Peter Beyer, Deputy Executive Director, GARDP</li> <li>Joachim Seybold, Deputy Medical Director, Charité - Universitätsmedizin Berlin</li> <li>Veronika von Messling, Director-General for Life Sciences, Federal Ministry of Education and Research, Germany</li> </ul>

8:50-9:00

#### **Opening Remarks**

• Muna Abu Sin, AMR Ambassador, Federal Ministry of Health, Germany

#### SESSION 1

### AMR in pediatric populations: challenges and successes

**Chair: Marcus Mall** 

Director, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine,

Charité - Universitätsmedizin Berlin

#### 9:05-10:30

#### Setting the scene:

- AMR in pediatric populations: Angela Dramowski, pediatric infectious diseases/infection prevention specialist and clinician researcher at Stellenbosch University's Department of Pediatrics and Child Health in Cape Town, South Africa (online)
- Updated WHO recommendations on management of serious bacterial infection in young infants: Karen Edmond, Scientist, Newborn Health Unit, Maternal, Newborn, Child and Adolescent Health and Ageing, WHO

#### Panel discussion:

- Angela Dramowski, Head of Clinical Unit General Pediatrics, Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University (online)
- Karen Edmond, Scientist, Newborn Health Unit (NBH), Maternal, Newborn, Child and Adolescent Health and Ageing, WHO
- Elias Iosifidis, Pediatric Department, Aristotle University of Thessaloniki, Greece
- Tobias Tenenbaum, Head of Clinic for Child and Adolescent Medicine, Sana Klinikum Lichtenberg, Berlin, President German Pediatric Infectious Diseases Society (DGPI)

#### **Questions & Answers**

10:30-11:00

#### Coffee Break and Networking

#### SESSION 2

# Innovative clinical trials and platforms for new and neglected antimicrobials Chair: Leif Erik Sander

Director, Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin

#### 11:00-12:30

### Setting the scene:

• Seamus O'Brien, R&D Director, GARDP

## Panel discussion:

- Seamus O'Brien, R&D Director, GARDP
- Beate Kampmann, Director, Charité Centre for Global Health, Charité Universitätsmedizin Berlin
- Gopinath Krishnamoorthy, Microbiologist, Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité Universitätsmedizin Berlin

## **Questions & Answers**

12:35-14:00	Lunch Break
	SESSION 3
	Breaking down access barriers for antibiotics & stewardship
	Chair: Peter Beyer
	Deputy Executive Director, GARDP
14:00-15:30	Setting the scene:
	Claude Mambo Muvunyi, Director General, Rwanda RBC
	Panel discussion:
	Daniela Carla de Souza, President of Latin American Sepsis Institute, University of São
	Paulo, Brazil
	Miriam Stegemann, Antimicrobial Stewardship, Charité - Universitätsmedizin Berlin
	Claude Mambo Muvunyi, Director General, Rwanda RBC
	Questions & Answers
15:30-15:45	Wrap-up/Closing:
	Beate Kampmann, Charité - Universitätsmedizin Berlin
	Peter Beyer, GARDP

# Symposium's Organizers

# <u>Charité Center for Global Health (CCGH) in collaboration with the Antimicrobial Stewardship Program at Charité - Charité - Universitätsmedizin Berlin</u>

Charité - Universitätsmedizin Berlin is one of the largest university hospitals in Europe. Many of the approximately 100 clinics and institutes at Charité have many years of experience in the field of Global Health, including in antimicrobial stewardship. Charité has established some highly visible networks and activities in this field, including the World Health Summit in 2009.

In January 2023, the Charité Center for Global Health was established with the aim to bring together the partners in global health research at the Charité and across Berlin, where strong global health groups and their international partnerships have already developed over the last few years, including in the field of AMR.

The **Charité Center for Global Health** aims to develop strong internal, local, national and international activities and partnerships in the field of global health, and to support and advance research, teaching and collaboration with policy makers and all stakeholders in the field of global health.

## WEBSITE: https://globalhealth.charite.de/en/

With the implementation of the formal institutional **Charité antimicrobial stewardship (AMS) program**, Charité established a rational, systematic approach to the use of antimicrobial agents to achieve optimal outcomes in pediatric and adult patients. The Charité AMS team promotes and monitors healthcare system-wide judicious use of antimicrobials to preserve their future effectiveness. The multiprofessional Charité AMS team is led by clinical infectious diseases specialists and pharmacists and works

closely with CCGH. Expert AMS activities include national and international collaborations to combat the spread of AMR and its challenges beyond borders and continents.

WEBSITE: <a href="https://infektiologie.charite.de/en/services/antibiotic stewardship abs/">https://infektiologie.charite.de/en/services/antibiotic stewardship abs/</a>

### **GARDP**

The Global Antibiotic Research & Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP was created by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally founded in 2018 to ensure that everyone who needs antibiotics receives effective and affordable treatment. GARDP is funded by the governments of Australia, Germany, Japan, Monaco, the Netherlands, the Public Health Agency of Canada, South Africa, Switzerland, the United Kingdom, the Canton of Geneva, as well as the European Union, the RIGHT Foundation, Wellcome Trust and private foundations. GARDP is registered under the legal name GARDP Foundation.

WEBSITE: <u>www.gardp.org</u>